US 9278096
Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
granted A61KA61K31/495A61P
Quick answer
US patent 9278096 (Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity) held by Takeda Pharmaceuticals North America, Inc. expires Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceuticals North America, Inc.
- Grant date
- Tue Mar 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 26
- CPC classes
- A61K, A61K31/495, A61P, A61P1/14, A61P11/00